Indication

Blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive hematologic malignancy that arises from clonal precursors of plasmacytoid dendritic cells. Read more about Blastic plasmacytoid dendritic cell neoplasm

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Blastic plasmacytoid dendritic cell neoplasm therapies.

Showing 1–2 of 2 drugs

ELZONRIS (tagraxofusp-erzs)

ANTINEOPLASTIC - CD123-DIRECTED CYTOTOXIN CONJUGATE·BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
STEMLINE THERAP
Filter & compare in the drug finder →Opens the drug finder with Blastic plasmacytoid dendritic cell neoplasm preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Blastic plasmacytoid dendritic cell neoplasm.

Blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive hematologic malignancy that arises from clonal precursors of plasmacytoid dendritic cells.

The disease most commonly presents in older adults, showing a marked male predominance, although it can manifest across any age group.

It primarily affects the skin, bone marrow, peripheral blood, and lymph nodes, frequently presenting as violaceous or purpuric cutaneous nodules, plaques, or ulcerated tumors alongside cytopenias and hepatosplenomegaly.

Pathophysiologically, the malignant cells exhibit a distinct blastic morphology and characteristic immunophenotypic expression, typically co-expressing CD4, CD56, and CD123.

Personalize your experience

Follow Blastic plasmacytoid dendritic cell neoplasm and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it